[EATG Global HIV News daily digest] Digest #29-2010

[EATG Global HIV News daily digest]

Global HIV News Daily Digest

Copied as fair use  -  Ana  -





Latest Headlines




  Malaria: Nose of mosquito transplanted
  Tuberculosis & Malaria Tuesday 16 February 2010
					
  
Scientists have successfully transplanted most of the "nose" of the
mosquito that spreads malaria into frog eggs and fruit flies and are
employing these surrogates to combat the spread of the deadly and
debilitating disease that afflicts 500 million people.
  SOURCE:
The Medical News




  Europeans spend billions on fake medicines: survey
  EU Policy Tuesday 16 February 2010
					
  
Western Europeans spend an estimated 10.5 billion euros ($14.3 billion)
a year on illicitly sourced medicines, many of them counterfeit,
according to a Pfizer-sponsored survey published on Tuesday.
  SOURCE:
REUTERS




  Letter to Partners 2010: Michel Sidibé, Executive Director, UNAIDS
  World Policy Tuesday 16 February 2010
					
  
In his 2010 letter to partners, Mr Michel Sidibé takes stock of his
first twelve months in office as UNAIDS Executive Director, and
provides his vision for the coming years. 
  SOURCE:
UNAIDS




  Civil society: Have your say on community systems strengthening!
  World Policy Tuesday 16 February 2010
					
  
The Global Fund to fight AIDS, Tuberculosis and Malaria (Global Fund)
has developed a community systems strengthening (CSS) Framework in
collaboration with other stakeholders including UNAIDS to clarify the
range of community strengthening activities the Global Fund is mandated
to support. 
  SOURCE:
UNAIDS




  Adding vicriviroc to antiretrovirals cuts HIV viral load
  Treatment Tuesday 16 February 2010
					
  
In treatment-experienced patients with HIV, addition of vicriviroc to
optimized antiretroviral therapy further decreases viral load and
improves CD4 counts, according to a phase 2 trial.
  SOURCE:
Medscape Today




  Raltegravir effective against HIV for nearly 2 years in those with drug resistant viruses
  Treatment Tuesday 16 February 2010
					
  
"We are encouraged that these data demonstrate the efficacy and
tolerability profile of Isentress in combination with other anti-HIV
medicines in treatment-experienced patients for up to 96 weeks."
  SOURCE:
Medscape Today




  Detectable viral load in CSF risk associated with neurological problems in patients taking HIV treatment 
  Treatment Tuesday 16 February 2010
					
  
Detectable viral load in cerebrospinal fluid is associated with
neurological symptoms in patients receiving HIV treatment who have an
undetectable viral load in their blood, French investigators report in
the March 1st edition of Clinical Infectious Diseases. 
  SOURCE:
Aidsmap




  Gay men’s risk of acquiring HIV is similar to the pre-HAART era despite widespread use of HAART 
  MSM Tuesday 16 February 2010
					
  
Although the widespread use of antiretroviral therapy could be expected
to make HIV-positive gay men less likely to pass on HIV during
unprotected sex than in the early 1990s, the risk of transmission
per-sexual-act is actually quite similar, Australian researchers report
in AIDS.
  SOURCE:
Aidsmap


----------------------------------------------------
DISCLAIMER
The articles in this digest represent a diversity of opinions on topics
of interest to the HIV treatment activist community. The EATG is not
responsible for their content. The articles posted in this digest do
not necessarily reflect EATG views or opinions.
FAIR USE NOTICE
The digest may contain copyrighted material which has not always been
specifically authorised by the copyright owner. Such material is made
available for educational purposes to advance the understanding of
scientific, ethical, legal and social issues. It is believed that this
constitutes a 'fair use' of any such copyrighted material. This
material is distributed without profit.


 

Information in this digest was accurately quoted during its compilation.




      
-------------- next part --------------
An HTML attachment was scrubbed...
URL: <http://mail.eatg.org/pipermail/eatg-forum_eatg.org/attachments/20100216/bb5e5483/attachment-0001.html>